Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01262443
Other study ID # ESREFO01
Secondary ID
Status Completed
Phase N/A
First received December 13, 2010
Last updated September 30, 2016
Start date November 2010
Est. completion date February 2014

Study information

Verified date May 2014
Source Ettore Sansavini Health Science Foundation
Contact n/a
Is FDA regulated No
Health authority Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of transcatheter ablation of atrial flutter with a standard irrigated catheter with flexible tip, as evaluated by percentual success of the procedure.


Description:

No more available data


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date February 2014
Est. primary completion date January 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Both sexes; age>18 yrs

- ECG documentation of at least 2 episodes of common atrial flutter or evidence of ongoing atrial flutter.

- No contraindications to transcatheter radiofrequency ablation by a standard 4mm irrigated flexible tip catheter

- Patients willing to accept the tests and to follow standard procedures

- Patients who understand the nature of the procedure and who are willing to participate and to sign the informed consent before enrollment

Exclusion Criteria:

- Atrial fibrillation

- Any arrhythmia requiring antiarrhythmics in the 6 months post procedure

- Intra atrial thrombosis

- NYHA class IV

- Unstable Angina or Acute Myocardial Infarction (AMI) in the last 3 month

- Untreated Wolf Parkinson White syndrome

- Contraindications to oral anticoagulation

- Life expectancy < 12 month

- Major surgery or interventional procedure already planned in the 6 month following ablation

- Pregnancy or breast-feeding

- Participation in another study

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Radiofrequency Ablation
Radiofrequency ablation by a standard 4mm irrigated flexible tip catheter

Locations

Country Name City State
Italy Maria Cecilia Hospital Cotignola RA
Italy Maria Pia Hospital Torino TO

Sponsors (1)

Lead Sponsor Collaborator
Ettore Sansavini Health Science Foundation

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentual success of the procedure during the hospitalization Procedural success is defined as evidence of bidirectional block of cava tricuspidal istmus. The presence of block will be evaluated by mapping the electrical activation of the right atrium before and after pacing from thecoronary synus. Up to 4 days No
Primary Percentual success of the procedure at 3 months from procedure Procedural success is defined as evidence of bidirectional block of cava tricuspidal istmus. The presence of block will be evaluated by mapping the electrical activation of the right atrium before and after pacing from thecoronary synus. 3 months No
Primary Percentual success of the procedure at 6 months from procedure Procedural success is defined as evidence of bidirectional block of cava tricuspidal istmus. The presence of block will be evaluated by mapping the electrical activation of the right atrium before and after pacing from thecoronary synus. 6 months No
Secondary •Synus rhythm maintenance in the absence of antiarrhythmics within 6 month from procedure. Up to 4 days; 3-6 month No
Secondary Duration of ablation procedure, number of radiofrequency erogations, duration and total energy given Up to 4 days Yes
Secondary Safety of the procedure recording of procedure-related complications Up to 4 days Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Terminated NCT02317029 - Comparison of Oxygen Interventions and Defibrillator Efficiency N/A
Recruiting NCT01563848 - Cryoablation in Patients With Atrial Flutter Phase 2
Completed NCT01229254 - Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter Phase 2
Completed NCT02065388 - Pharmacogenetic Dosing of Warfarin Phase 3
Completed NCT00839657 - Clarification of Optimal Anticoagulation Through Genetics Phase 3
Completed NCT00232232 - Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia Phase 4
Completed NCT04884100 - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening N/A
Completed NCT05468281 - RAFF5 Proposal: Improve the Quality and Safety of Patients Seen in the Emergency Department for Acute Atrial Fibrillation and Flutter
Completed NCT03627143 - Decreasing Hospital Admissions From the ED for AAFF N/A
Completed NCT02917538 - A Randomized Trial of Contact Force in Atrial Flutter Ablation N/A
Enrolling by invitation NCT05903313 - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Recruiting NCT05755074 - Ablation of Typical Right Atrial Flutter N/A
Recruiting NCT05883631 - RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy. N/A
Recruiting NCT03272620 - Atrial Fibrillation at the Viennese University Emergency Department N/A
Completed NCT02810938 - MIFI Flutter Registry - Ablation of Atrial Flutter With IntellaTip Sensor Technology
Recruiting NCT02591875 - Atrial Flutter Ablation in a Real World Population N/A
Completed NCT02268799 - High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter N/A
Completed NCT01914497 - Dipole Density Mapping of Typical Atrial Flutter N/A
Active, not recruiting NCT01976507 - Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism Phase 4